TIDMIMM

Immupharma PLC

24 March 2017

 
   24 MARCH 2017

IMMUPHARMA'S CHAIRMAN TO PRESENT AT MASTER INVESTOR SHOW

Date: Saturday 25 March 2017, Business Design Centre, Islington

ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, confirms that Tim McCarthy, ImmuPharma's Chairman, will be presenting at this forthcoming Saturday's 'Master Investor Show', at the Business Design Centre, in Islington London. Mr McCarthy's slot is confirmed as 11.20 am in the Gallery Suite.

The Master Investor Show aims to inform, inspire and educate private investors. It brings together investors of all portfolio sizes to hear keynote talks from high profile investors with which to gain access to new investment opportunities.

Commenting, Tim McCarthy, Chairman of ImmuPharma, said: "ImmuPharma has started 2017 with excellent progress being achieved. Our ongoing pivotal Phase III Lupuzor(TM) trial has completed recruitment of the 200 patients required for the study and we are on track to announce top line results in Q1 2018. We also successfully completed this month a GBP4.1 million fundraising with support from both existing and new investors. We therefore look forward to presenting the ImmuPharma story to those attending the Master Investor Show this forthcoming weekend."

An updated corporate presentation will be available on ImmuPharma's website from next Monday 27 March 2017: "www.immupharma.org/investors".

Ends

 
 For further information please 
  contact: 
                                           + 44 (0) 20 
   ImmuPharma plc (www.immupharma.org)       7152 4080 
   Tim McCarthy, Chairman 
   Lisa Baderoon, Head of Investor 
    Relations                             + 44 (0) 7721 
    Twitter: @immupharma                      413496 
   Northland Capital Partners Limited 
    (NOMAD & Broker) 
    Patrick Claridge, David Hignell, 
    Michael Mackintosh, Corporate 
    Finance                               +44 (0)20 3861 
    Rob Rees, Corporate Broking                6625

Notes to Editors

ImmuPharma PLC

ImmuPharma is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange (LSE:IMM), focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma is led by a commercially focused Board and management team with extensive experience.

Lupuzor(TM)

Lupuzor(TM) (also referred to as Forigerimod, or P140) is ImmuPharma's lead compound and a potential treatment for lupus (or Systemic Lupus Erythematosus), a chronic, potentially life-threatening auto-immune disease. Lupuzor(TM) has a novel mechanism of action aimed at modulating the body's immune system so that it does not attack healthy cells, and avoids causing adverse side effects. It has the potential to halt the progression of the disease in a substantial proportion of patients.

Lupuzor(TM) has been granted Fast Track status by the US FDA and approval to for its ongoing Phase III under Special Protocol Assessment (SPA).

The pivotal Phase III clinical study is entitled "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus". It is a pivotal study designed to demonstrate the safety and efficacy of IPP-201101 and as a last step prior to the filing of the drug for approval with the US Food & Drug Administration ("FDA") and the European Medicines Agency ("EMA"). For more information please visit: www.ClinicalTrials.gov/lupuzor

Commercial Opportunity

There are an estimated five million people globally suffering from Lupus, with approximately 1.5 million patients in the US, Europe and Japan (Source: Lupus Foundation of America). Current 'standard of care' treatments, including steroids and immunosuppressants, can potentially have either serious side effects for patients or limited effectiveness, with over 60% of patients not adequately treated. GSK's Benlysta is the first Lupus drug approved in over 50 years and paves the path to market for Lupuzor(TM). Based on conservative estimates, and taking into account that Benlysta is priced currently at approximately $30,000 per patient per year, Lupuzor(TM) would be entering a market with the potential for multi-billion dollar sales. For more information on Lupuzor(TM) please visit: www.lupuzor.com

The Master Investor Show is the UK's largest event, with around 4,000 visitors, aimed at informing, inspiring and educating private investors. It brings together private investors of all portfolio sizes to hear keynote talks from high profile investors with which to gain access to new investment opportunities. For more information go to: www.masterinvestor.co.uk

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAEAXDDADXXEFF

(END) Dow Jones Newswires

March 24, 2017 03:01 ET (07:01 GMT)

Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Immupharma Charts.
Immupharma (LSE:IMM)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Immupharma Charts.